HER2 therapies and gastric cancer: A step forward

World Journal of Gastroenterology

Volumn 19, Issue 37, 2013, Pages 6165-6169

  de Mello, Ramon Andrade ^a,b   Marques, Andrea Marin ^c   Araújo, António ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Unidade Santo Tirso   (Portugal)

Author keywords

C Met; Gastric cancer; Human epidermal growth factor receptor 2; Lapatinib; Pertuzumab; Trastuzumab

Indexed keywords

CAPECITABINE; CISPLATIN; CRIZOTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LAPATINIB; PERTUZUMAB; PLACEBO; SCATTER FACTOR; TRASTUZUMAB;

ANEMIA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

C-MET; GASTRIC CANCER; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; TRASTUZUMAB;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84885578812     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i37.6165     Document Type: Review

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]
2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
3. Stoss O, Nagelmeier I, Zielinski D, Rüschoff J. The ToGA (Trastuzumab for GAstric Cancer) Trial: Importance from a Biomarker Perspective. Connection 2010; 2010: 52-53
4. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Lipatov O, Al-Sakaff N, See C, Rueschoff J, Cutsem EV. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009; 27: 4556
5. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36 [PMID: 17208639 DOI: 10.1016/ S0140-6736(07)60028-2]
6. Ananiev J, Gulubova M, Manolova I, Tchernev G. Prognostic significance of HER2/neu expression in gastric cancer. Wien Klin Wochenschr 2011; 123: 450-454 [PMID: 21739203 DOI: 10.1007/s00508-011-0025-9]
7. Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs 2010; 70: 2259-2267 [PMID: 21080742 DOI: 10.2165/11205900-000000000-00000]
8. de Mello RA, Gregório T, Cardoso T. Chylous ascites due to signet ring cell gastric adenocarcinoma. Niger J Clin Pract 2012; 15: 487-490 [PMID: 23238204 DOI: 10.4103/1119-3077.1 04536]
9. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; (3): CD004064 [PMID: 20238327]
10. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 2010; 36 Suppl 3: S11-S15 [PMID: 21129604]
11. Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol 2011; 8: 369-383 [PMID: 21647199 DOI: 10.1038/nrgas-tro.2011.81]
12. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65 [PMID: 20208134 DOI: 10.3233/CLO-2009-0497]
13. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146: 264-275 [PMID: 20385184 DOI: 10.1016/j.jconrel.2010.04.009]
14. Song Y, Huang J, Wang JW. [Relationship between HER2/ neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma]. Chin J Cancer 2010; 29: 76-81 [PMID: 20038314]
15. Bang YJ, Chung HC, Xu JM, Lordick F, Sawaki A, Lipatov O, Al-Sakaff N, See CG, Rueschoff J, Van Cutsem E. Pathological features of advanced gastric cancer: relationship to human epidermal growth factor receptor 2 positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009; 27: 18s
16. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529 [PMID: 18441328 DOI: 10.1093/annonc/ mdn169]
17. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23: 2656-2662 [PMID: 22689179 DOI: 10.1093/annonc/ mds104]
18. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805 [PMID: 18422971 DOI: 10.1111/j.1365-2559.2008.03028.x]
19. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst 2009; 101: 1306-1307 [PMID: 19755679 DOI: 10.1093/jnci/djp341]
20. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-1902 [PMID: 10223227]
21. Okines AF, Thompson LC, Cunningham D, Wotherspoon A, Reis-Filho JS, Langley RE, Waddell TS, Noor D, Eltahir Z, Wong R, Stenning S. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 2013; 24: 1253-1261 [PMID: 23233651 DOI: 10.1093/annonc/mds622]
22. Pazo Cid RA, Antón A. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol 2013; 85: 350-362 [PMID: 23021388 DOI: 10.1016/ j.critrevonc.2012.08.008]
23. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH. HER2 diagnostics in gastric cancerguideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457: 299-307 [PMID: 20665045 DOI: 10.1007/s00428-010-0952-2]
24. Gunturu KS, Woo Y, Beaubier N, Remotti HE, Saif MW. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol 2013; 5: 143-151 [PMID: 23450234 DOI: 10.1177/1758834012469429]
25. Pishvaian M, Sakaeva D, Hsieh R. A global, multi-center phase II trial of lapatinib plus capecitabine in gastric cancer. J Clin Oncol 2011; 29 Suppl 4: abstr 88
26. Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013; 8: e54014 [PMID: 23516391 DOI: 10.1371/journal.pone.0054014]
27. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 2012; 30: 3287-3296 [PMID: 22869872 DOI: 10.1200/JCO.2011.40.3774]
28. Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011; 306: 171-179 [PMID: 21458915 DOI: 10.1016/j.canlet.2011.03.002]
29. Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011; 17: 5060-5070 [PMID: 21700765 DOI: 10.1158/1078-0432.ccr-10-2927]
30. Sendur MA, Aksoy S, Altundag K. Pertuzumab in HER2-positive breast cancer. Curr Med Res Opin 2012; 28: 1709-1716 [PMID: 22953713]
31. Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010; 10: 489-491 [PMID: 21147694 DOI: 10.3816/CBC.2010.n.065]
32. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119 [PMID: 22149875 DOI: 10.1056/NEJMoa1113216]
33. Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 1131-1137 [PMID: 20124183 DOI: 10.1200/JCO.2009.24.1661]
34. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461-471 [PMID: 23602601 DOI: 10.1016/S1470-2045(13)70130-X]
35. Boku N. HER2-positive gastric cancer. Gastric Cancer 2013; Epub ahead of print [PMID: 23563986 DOI: 10.1007/s10120-013-0252-z]
36. de Mello RA, de Vasconcelos A, Ribeiro RA, Pousa I, Afonso N, Pereira D, Rodrigues H. Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies. Recent Pat DNA Gene Seq 2012; 6: 56-63 [PMID: 22239685]
37. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009; 100: 487-493 [PMID: 19156142 DOI: 10.1038/sj.bjc.6604885]
38. Bystricky B, Okines A, Cunningham D. Targeting Her-2 in gastric cancer-incorporation of trastuzumab into the treatment of operable disease. Gastrointestinal Cancer: Targets and Therapy 2011; 1: 41-52 [DOI: 10.2147/GICTT.S18495]
39. Gong SJ, Jin CJ, Rha SY, Chung HC. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 2004; 214: 215-224 [PMID: 15363548 DOI: 10.1016/j.canlet.2004.04.029]
40. Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, Kobayashi M, Hirohashi S. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with longterm survival of patients. Cancer 1993; 72: 3179-3184 [PMID: 7902202]
41. Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat 2009; 118: 113-124 [PMID: 19415485 DOI: 10.1007/s10549-009-0412-3]
42. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulinlike growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-11128 [PMID: 16322262 DOI: 10.1158/0008-5472.can-04-3841]
43. Kaji M, Yonemura Y, Harada S, Liu X, Terada I, Yamamoto H. Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther 1996; 3: 393-404 [PMID: 8988842]
44. Kubicka S, Claas C, Staab S, Kühnel F, Zender L, Trautwein C, Wagner S, Rudolph KL, Manns M. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci 2002; 47: 114-121 [PMID: 11837710]
45. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, deSouza NM, Leach MO, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de Bono JS. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011; 29: 1271-1279 [PMID: 21383285 DOI: 10.1200/JCO.2010.31.0367]
46. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011; 29: 4803-4810 [PMID: 22042947 DOI: 10.1200/JCO.2011.35.4928]
47. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011; 22: 2610-2615 [PMID: 21415234 DOI: 10.1093/annonc/mdr021]
48. Nam HJ, Ching KA, Kan J, Kim HP, Han SW, Im SA, Kim TY, Christensen JG, Oh DY, Bang YJ. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol Cancer Ther 2012; 11: 439-451 [PMID: 22135232 DOI: 10.1158/1535-7163. mct-11-0494]
49. Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, Ryoo BY, Lee JL, Chang HM, Kim TW, Kang YK. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 2012; 106: 1039-1044 [PMID: 22343617]